[Heparan sulphate in association with indobufen in the treatment of chronic peripheral obliterative arteriopathy of the lower extremities. Controlled clinical trial].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Rossini A;Rossini A; Tascino C; Costa F
  • Source:
    Minerva cardioangiologica [Minerva Cardioangiol] 1998 Nov; Vol. 46 (11), pp. 457-69.
  • Publication Type:
    Clinical Trial; Controlled Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • Language:
    Italian
  • Additional Information
    • Transliterated Title:
      Eparansolfato in associazione ad indobufene nella terapia delle arteriopatie obliteranti croniche periferiche degli arti inferiori. Studio clinico controllato.
    • Source:
      Publisher: Edizioni Minerva Medica Country of Publication: Italy NLM ID: 0400725 Publication Model: Print Cited Medium: Print ISSN: 0026-4725 (Print) Linking ISSN: 00264725 NLM ISO Abbreviation: Minerva Cardioangiol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Torino : Edizioni Minerva Medica
    • Subject Terms:
      Arterial Occlusive Diseases/*drug therapy ; Heparitin Sulfate/*therapeutic use ; Leg/*blood supply ; Phenylbutyrates/*therapeutic use ; Platelet Aggregation Inhibitors/*therapeutic use; Adult ; Aged ; Arterial Occlusive Diseases/complications ; Female ; Humans ; Intermittent Claudication/drug therapy ; Intermittent Claudication/etiology ; Isoindoles ; Male ; Middle Aged
    • Abstract:
      Background: The aim of this study has been to assess the efficacy and the safety of heparansulphate administered with indobufen in the treatment of occlusive arterial disease.
      Methods: In a controlled open study, nineteen out-patients with Fontaine's stage II occlusive arterial disease since one year were randomly assigned to treatment with indobufen 200 mg/day or indobufen 200 mg/day and heparansulphate 200 mg/day for 6 months. Efficacy assessments were based on functional evaluations (pain-free sub-maximal exercise ergometric test, ankle-arm pressure ratio at rest and after induced ischemia), on hemocoagulative parameters and on physical signs and subjective symptoms assessed monthly over the whole period of treatment. All patients but one who was lost to follow-up completed the study treatment period as foreseen by the experimental protocol.
      Results: The results of the study show an improvement of 10.89% (day 30), 15.92% (day 60), 21.04% (day 90), 24.19% (day 120), 25.18 (day 150) 28.84% (day 180) end of study in ergometric test pain-free interval obtained by patients treated with heparansulphate and indobufen with respect to patients receiving indobufen alone. Also hemocoagulative parameters and signs and patients' subjective symptoms were positively influenced by the association heparansulphate and indobufen.
      Conclusions: On the whole, the results of the study indicate that heparansulphate in association with antiplatelet therapy with indobufen has a beneficial effect in the treatment of peripheral occlusive arterial disease.
    • Accession Number:
      0 (Isoindoles)
      0 (Phenylbutyrates)
      0 (Platelet Aggregation Inhibitors)
      6T9949G4LZ (indobufen)
      9050-30-0 (Heparitin Sulfate)
    • Publication Date:
      Date Created: 19990420 Date Completed: 19990430 Latest Revision: 20121115
    • Publication Date:
      20240829
    • Accession Number:
      10207294